title: Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
abstract: The human epidermal growth factor receptor (EGFR) has been established as an attractive target for lung cancer therapy. However, an acquired EGFR T790M gatekeeper mutation is frequently observed in patients treated with first-line anticancer agents such as gefitinib and erlotinib to cause drug resistance, largely limiting the application of small-molecule kinase inhibitors in EGFR-targeted chemotherapy. Previously, the reversible pan-kinase inhibitor staurosporine and its several analogs such as Gö6976 and K252a have been reported to selectively inhibit the EGFR T790M mutant (EGFRT790M) over wild-type kinase (EGFRWT), suggesting that the staurosporine scaffold is potentially to develop the wild-type sparing reversible inhibitors of EGFRT790M. Here, we systematically evaluated the inhibitor response of 28 staurosporine scaffold-based compounds to EGFR T790M mutation at structural, energetic, and molecular levels by using an integrated in silico-in vitro analog-sensitive (AS) kinase technology. With the strategy, we were able to identify 4 novel wild-type sparing inhibitors UCN-01, UCN-02, AFN941, and SB-218078 with high or moderate selectivity of 30-, 45-, 5-, and 8-fold for EGFRT790Mover EGFRWT, respectively, which are comparable with or even better than that of the parent compound staurosporine (24-fold). Molecular modeling and structural analysis revealed that van der Waals contacts and hydrophobic forces can form between the side chain of mutated residue Met790 and the pyrrolidinone moiety of inhibitor ligand UCN-02, which may simultaneously improve the favorable interaction energy between the kinase and inhibitor, and reduce the unfavorable desolvation penalty upon the kinase-inhibitor binding. A hydroxyl group of UCN-02 additional to staurosporine locates at the pyrrolidinone moiety, which can largely alter the electronic distribution of pyrrolidinone moiety and thus promote the intermolecular interaction with Met790 residue. This can well explain the measured higher selectivity of UCN-02 than staurosporine for mutant over wild-type kinase.
authors.affiliation: Department of Pharmacy, The Affiliated Hospital of Nantong University, Dongtai, China.
authors.forename: Xiaoyun
authors.initials: X
authors.lastname: Song
authors.affiliation: Department of Pharmacy, The Affiliated Hospital of Nantong University, Dongtai, China.
authors.forename: Xingcai
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Pharmacy, The Affiliated Hospital of Nantong University, Dongtai, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Ding
mesh_terms: D003198:Computer Simulation; D015195:Drug Design; D066246:ErbB Receptors / Q000737:chemistry / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics*; D008958:Models, Molecular; D009154:Mutation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D019311:Staurosporine / Q000031:analogs & derivatives*; D013329:Structure-Activity Relationship
chemical_list: D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors; D019311:Staurosporine
keywords: T790M gatekeeper mutation; acquired drug resistance; analog-sensitive kinase technology; chemotherapy; human epidermal growth factor receptor; lung cancer; rational drug discovery; staurosporine scaffold